



# HEALTHCARE

---

*The Indian API (Active pharmaceutical ingredient) saga from Bust to Boom*

---

April 2022



# Aditya Khemka

## Fund Manager, InCred Healthcare PMS

Historically, most Indian Pharma companies came into existence by starting off as an API manufacturers . During the 1980s, India was the largest manufacturer and exporter of raw materials and API. However, when China started competing with lower pollution controls and capital and revenue subsidies in 1990s, the Indian API industry fell sick as the customer base shifted by and large to the cheaper Chinese manufacturers .

### The Indian API industry – is on a revival path

Over the last 4-5 years, we have begun to see a turnaround in the Indian API industry with the players who managed to survive the last 3 decades of intense competition from China. These companies survived for 30 years because they either had a differentiated product portfolio or were fiercely cost-competitive compared to their Chinese counterparts.

However, since 2017-2018, China has also implemented pollution controls across industrial parks and provinces to achieve their carbon emission goals. This added to the existing inflation in Chinese labor/power cost all of which are critical inputs in manufacturing raw materials and API. Hence, we are currently witnessing a plethora of Capex in the Indian API industry. Customers of the Chinese API seem to be looking for an alternate supplier to de-risk their supply chains. Further, the geopolitical narrative necessitates a diversification of Chinese pharma supply as a national security measure.

### Why did the Indian API stocks do well and then tumble?

Many API stocks gave manifold returns in 9MFY21. However, subsequently, we have seen the same stocks declining anywhere between 25% to 75% over the last 2-3 quarters of FY22. We believe there are 2 fundamental factors that led to this:

a) Inventory rationalization at the customer's end; b) margin pressure as input costs rise.

### Will the trend of lower margins/volume growth sustain?

We believe it is unlikely that margin pressures and low volume growth would sustain. API companies generally work on a cost-plus model but get bound in annual/semi-annual contracts with their customers where prices tend to be fixed over the tenure. Hence, the price pass on eventually happens albeit with a lag. Volume growth in the last 2-3 quarters has been lower due to the high base of last year. However, in the coming year, volume growth may likely normalize as the current base of volume is lower than normal (inventory destocking).

## How is the InCred Healthcare Portfolio positioned?

We are optimistic about the API business over the next 3–5 years. We believe that the Capex cycle may coincide with high volume growth and price stability once margins are normalized (likely sometime in 1QFY23–2QFY23). At InCred Healthcare PMS, we are overweight the sector with 21% of our fund deployed in the space vs 16% for the benchmark.

## What are the risks to our thesis?

With a new surge of Covid related restrictions in China, we could potentially see another round of price increases and supply bottlenecks in raw materials from China. However, we believe that now the industry is relatively more prepared for such shocks than last year and the worst is already in the price. However, we cannot rule out a delay in the normalization of margins if another supply shock of raw materials were to set in the near future.


## Case study of Neuland Labs

Neuland Labs is a pure-play API manufacturer for several domestic and international pharmaceutical companies. The company has two USFDA- approved facilities that manufacture over 75 APIs addressing 36 therapies. NLL’s APIs are primarily marketed in highly regulated markets such as the US, Europe, and Japan (accounting for over 75% of its sales).

Revenue has grown at a CAGR of 13 % over FY16–FY21. The company has three business segments, namely

- 1) prime API
- 2) niche API
- 3) CMS (Commercial + development).

Over the years, NLL has shifted its focus from the high-volume, low-margin segment (Prime API) to high-margin complex products (niche API/CMS). The revenue contribution from the prime API segment reduced to 46% in FY21 from 54% in FY16. Contribution from niche APIs has been in the range of 21%–25% between FY16–21 while CMS revenues have increased to 30% in FY21 from 17% in FY16.



Source: InCred PMS Research team

Margins are expected to improve (~15% in 9MFY22) on the back of a strong order book, better traction in the GDS business, cost optimization measures, and improved product and revenue mix within CMS business.

We believe Neuland is in a sweet spot given that global and Indian pharma players are looking at the China+1 strategy for sourcing raw material. To cater to the increased demand, the company has invested in additional capacities (Unit-3) which will provide for strong growth over the next few years. Over the last 4 years, the company has added 27 molecules in its CMS segment (57 in 3QFY19 to 81 in 3QFY22) across the pre-clinical to development and commercial stage. Hence, Neuland is also a second derivative play on pharmaceutical innovators.

Like any other API company, Neuland too is seeing an escalation in RM pricing which has led to margin contraction. However, we believe this impact is transient in nature. API companies are bound by contractual agreements which restrict them from taking immediate price hikes. However, once the contracts are renewed, the increase in raw material costs is fully / partially passed on. We expect Neuland's profitability to improve hereon given the increased focus on specialty APIs, cost rationalization initiatives, and better product mix in the CMS business.

Neuland is trading at 7x FY24E EV/EBITDA. We value the stock at 12x EV/EBITDA to capture the revival in margins and better product mix going ahead. We see that Custom Synthesis players in India/Internationally are trading at >20x EV/EBITDA. We value Neuland at a discount due to exposure to generic APIs which trade at a much lower multiple.

## Disclaimer

---

Any information contained in this material shall not be deemed to constitute an advice, an offer to sell/purchase or as an invitation or solicitation to do for security of any entity and further InCred Capital Wealth Portfolio Managers Private Limited (InCred PMS) and its employees/directors shall not be liable for any loss, damage, liability whatsoever for any direct or indirect loss arising from the use of this information. Recipients of this information should exercise due care and caution and read the Disclosure Document (if necessary obtaining the advice of finance/other professionals) prior to taking any decision on the basis of this information which is available on [www.incredsecurities.com](http://www.incredsecurities.com)

InCred PMS has not independently verified all the information and opinions given in this material. Accordingly, no representative or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this material. The performance related information provided herein is not verified by SEBI/ any regulatory authority nor has SEBI certified the accuracy or adequacy of the same. We have included statements / opinions / recommendations in this document, which contain words, or phrases such as "will", "expect", "should", "believe" and similar expressions or variations of such expressions, that are "forward looking statements". Actual results may differ materially from those suggested by the forward looking statements due to risk or uncertainties associated with our expectations with respect to, but not limited to, exposure to market risks, general economic and political conditions in India and other countries globally, which have an impact on our services and / or investments, the monetary and interest policies of India, inflation, deflation, unanticipated turbulence in interest rates, foreign exchange rates, equity prices or other rates or prices etc.

Inception date of the Strategy 15th February, 2021. InCred Portfolio returns are composite returns of all the Portfolios aligned to the investment approach. Returns for individual client may differ depending on time of entry in the Portfolio. Past performance may or may not be sustained in future and should not be used as basis for comparison with other investments. Returns for 1 year or lesser time horizon are absolute returns. Returns have been calculated using Time Weighted Rate of Return method (TWRR) as prescribed by the SEBI. Closing Price as sourced from Bloomberg. Market Cap is according to AMFI Classification which happens half yearly. Classification as on Dec 2020. The sector(s)/stock(s)/issuer(s) mentioned in this document do not constitute any recommendation of the same and the Scheme may or may not have any future position in these sector(s)/stock(s)/issuer(s). The strategy / investment approach / framework mentioned herein is currently followed by the scheme and the same may change in future depending on market conditions and other factors.